| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4993 | BEBT-908 | 1235449-52-1 | BEBT-908,extracted from patent US/20120088764A1, Compound example 243, is a novel, potent and selectivePI3Kαinhibitor with anIC50<0.1 μM, it also inhibits HDAC with 0.1 μM≤IC50≤1 μM. |
|
V4519 | BGB-102 | 807640-87-5 | JNJ-26483327 (also known as BGB102; JNJ26483327; BGB-102) is a novel, potent, reversible and orally bioavailable small-molecule multitargeted tyrosine kinase inhibitor againstEGFR,HER2, andHER4withIC50s of 9.6 nM, 18 nM and 40.3 nM, respectively. |
|
V4702 | BI-0252 | 1818291-27-8 | BI-0252 is a novel, potent, highly selective, orally bioactiveMDM2-p53interaction inhibitor with anIC50of 4 nM. |
|
V4714 | BI-1408 | 2231075-94-6 | BI-1408, atetrahydroindazole derivative, is a novel,centrally efficacious and potentγ secretasemodulator with anIC50of 0.04 μM forAβ42. |
|
V4700 | BI-224436 | 1155419-89-8 | BI-224436,an investigational new drug under development for the treatment of HIV infection, is the first non-catalytic site integrase inhibitor (NCINI) withEC50values of less than 15 nM against different HIV-1 laboratory strains. |
|
V4762 | BI-2852 | 2375482-51-0 | BI-2852 (BI2852) isa novel and potentKRASinhibitorthat binds with nanomolar affinity to the SI/II pocket of KRAS, which is mechanistically distinct from covalentKRASG12Cinhibitors because it binds to a different pocket present in both the active and inactive forms ofKRAS. |
|
V4703 | BI-3663 | 2341740-84-7 | BI-3663 is a novel, potent,functional and highly selectivePTK2/FAK degrader based on PROTAC (proteolysis-targeting chimeras) technology, utilizing VHL (von Hippel-Lindau) and cereblon ligands to hijack E3 ligases for PTK2 degradation. |
|
V4709 | BI-3802 | 2166387-65-9 | BI-3802 (BI3802) is a novel and highly potentBCL6degrader which inhibits the BTB domain of BCL6 with anIC50of ≤3 nM; BI-3802 has demonstrated potent antitumor activityby inducing efficacious BCL6 protein degradation in several diffuse large B-cell lymphoma (DLBCL) cell lines. |
|
V4718 | BI-3812 | 2166387-64-8 | BI-3812 (BI3812) is novel, highly potent and efficaciousBCL6inhibitor with potential antitumor activity. |
|
V4708 | BI-671800 | 1093108-50-9 | BI-671800 is a novel, potent and highly specific antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CRTH2), with IC50 values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively. |
|
V4711 | BI8622 | 1875036-74-0 | BI-8622 is a novel, potent and specific inhibitor of the ubiquitin ligaseHUWE1with anIC50of 3.1 μM. |
|
V4713 | BI8626 | 1875036-75-1 | BI8626 is a novel, potent and specific inhibitor of the ubiquitin ligaseHUWE1with anIC50of 0.9 μM. |
|
V4913 | Bifluranol | 34633-34-6 | Bifluranol (formerly also known as BX-341; traded name Prostarex),a novel fluorinated bibenzyl anti-androgen, is a potent and synthetic nonsteroidal estrogen of the stilbestrol calss related to diethylstilbestrol that has been used as an antiandrogen in the United Kingdom in the treatment of benign prostatic hyperplasia. |
|
V5063 | Bisindolylmaleimide I HCl | 176504-36-2 | Bisindolylmaleimide I HCl (GF109203X; Gö 6850; BIM I) is a novel, highly selective, cell-permeable, and reversible PKC inhibitor with Kiof 14 nM). |
|
V4706 | BRD7-IN-1 | 2305379-66-0 | BRD7-IN-1, a novel BI7273 analog (a BRD7/9 inhibitor), is utilized in PROTACVZ185 by binding to a VHL ligand via a linker to form aPROTACVZ185 against BRD7/9 with DC50s of 4.5 and 1.8 nM, respectively. |
|
V5104 | Bruceantin (NCI165563; NSC165563) | 41451-75-6 | Bruceantin (also known as NSC165563), a novel anticancer quassinoid compound extracted from Brucea antidysenterica, is first isolated from Brucea antidysenterica which is a tree found and used in Ethiopia for the treatment of cancer such as leukemia, and the activity was observed against B16 melanoma, colon 38, and L1210 and P388 leukemia in mice. |
|
V4771 | Btk inhibitor 1 | 1412418-47-3 | BTK inhibitor 1, a pyrazolo[3,4-d]pyrimidine analog, is a novel and potent inhibitor of Btk kinase extracted from PCT Int. |
|
V4772 | Btk inhibitor 2 | 1558036-85-3 | Btk inhibitor 2 (BGB-3111 analog) is a Bruton's tyrosine kinase (BTK) inhibitor disclosed in patent US 20170224688 A1. |
|
V4994 | CAL-130 | 1431697-74-3 | CAL-130 is a novel, potent and selective PI3Kδ and PI3Kγ inhibitor with potential anticancer activity and with IC50s of 1.3 and 6.1 nM, respectively. |
|
V5103 | Calcium methyltetrahydrofolate (NSC173328) | 26560-38-3 | Calcium methyltetrahydrofolate (NSC173328), a synthetic derivative of folic acid, is the calcium salt of levomefolic acid, which has the potential for treatment of cardiovascular disease and advanced cancers such as breast and colorectal cancers. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
